LEEI Project
9
Years of experience
3
Players
1
Aim
The „LEEI Project“ brings together three dynamic players – KyooBe Tech, Bausch+Ströbel, and Fraunhofer – in a thrilling interdisciplinary collaboration.
In a groundbreaking and forward-thinking methodology, we employ electron beams for the inactivation of pathogens. This revolutionary approach not only enhances production efficiency, but also elevates vaccine quality, removing hazardous chemicals and ensures process reproducibilitvy.
Research Goal: The primary objective is to investigate the application of Low-Energy Electron Irradiation (LEEI) on cells, microbes, viruses, and other biological materials. Key focus areas include inactivation kinetics, cellular and molecular activation mechanism, and alterations in biological material.
KyooBe Tech is an emerging engineering company focusing on the development of innovative manufacturing platforms, that drives the pharmaceutical production of tomorrow. With an interdisciplinary team of motivated engineers and biotechnologists, we develop high-quality technological solutions for biological challenges in vaccines and cell and gene therapy. Our vision is to enable access of next-generation therapeutic methods to a broader patient population.
As a member of the Bausch + Ströbel group, KyooBe Tech specializes in developing innovative pharmaceutical process architectures. Our expertise includes the end-to-end development of LEEI systems—from concept to fully operational machines.
The filling and packaging lines from Bausch+Ströbel are used worldwide to fill syringes, vials, cartridges and ampoules with high-grade liquid and powder pharmaceutical products. Their expertise in the construction of GMP-compliant pharmaceutical systems is unmatched in the industry.
As a globally recognized leader in aseptic Fill & Finish solutions, Bausch + Ströbel offers decades of experience in pharmaceutical manufacturing. Their level of quality & hygienic designs makes them to a vital partner in the LEEI-Consortiums mission, especially for designing GMP-compliant processes.
Four Fraunhofer institutes lead the scientific forefront of this technology, continuously innovating and exploring new applications of LEEI-technologies. They conduct extensive pathogen studies to identify potential vaccine candidates, while also spearheading the development of the prototype system.
Fraunhofer brings extensive expertise in LEEI treatment and vaccine development. Equipped with a prototype LEEI system within a BSL-2 laboratory, the Fraunofer IZI institute is capable of conducting comprehensive studies, including animal trials.
Learn more about the winners of the Fraunhofer Prize for Human- and Environment-Centered Technology:
Awarded Project: Inactivating Pathogens with Low-Energy Electrons
Our journey
First virus inactivation
Innovation project granted by the Fraunhofer innovations fund
Filing of LEEI patent family
Grant by Bill & Melinda Gates Foundation
Licensing deal with Bausch+Ströbel
Foundation of KyooBe Tech GmbH
Launch of KyooBe Techs first LEEI 2.0 prototype
KyooBe Tech enters the market with it’s first Lab Scale Pilot Device
Parcipitate in a new generation of vacccine manufacturing!
Get in contact to learn and participate!